Moderna lays out organizational changes aimed at scaling for product launches in 2027 and 2028

Moderna said it is reorganizing parts of its leadership team to prepare for multiple product launches planned for 2027 and 2028, a move that indicates the company is trying to align commercial operations and execution across its pipeline of mRNA-based medicines.

In the announcement, Moderna said Dr. Stephen Hoge, the company’s President, will assume an expanded role that includes operational oversight of the Infectious Disease franchise, the Intismeran franchise, and the Rare Disease franchise. Intismeran is Moderna’s investigational program name within its mRNA platform, and the company frames it as a distinct franchise area rather than a single product.

Moderna also said Ester Banque will join the company as Chief Commercial Officer. The Chief Commercial Officer role is typically responsible for how products move from late-stage development into scaled commercialization, including planning for manufacturing readiness, market access strategy, and commercial execution once products are launched.

The company did not describe in the announcement how many launches are expected in each year, nor did it specify product names or targeted indications in the disclosed statement. It also did not provide timeline granularity beyond pointing to the 2027 and 2028 window.

Moderna has previously emphasized that its strategy depends on building a durable pipeline of mRNA medicines and expanding into multiple therapeutic areas. An organizational approach that divides work into franchise-like groups can be a way to concentrate expertise while still allowing for coordinated cross-functional execution when programs approach commercialization.

The changes announced Wednesday come at a time when biotech firms are increasingly focused on operational scaling, not just clinical progress. For a company like Moderna, which is still advancing multiple programs, the transition from research and clinical development into product launch readiness often requires different internal structures, including clearer ownership of commercial milestones and supply chain planning.

For investors and employees, the most immediate takeaway is who is being placed in charge of execution. By expanding the operational role of its President across infectious disease, intismeran and rare disease, Moderna is effectively centralizing oversight for major franchise segments ahead of planned launches later this decade.

Moderna did not provide further details in the public post about organizational reporting lines, job openings, or whether other leadership roles will change. It also did not disclose specific launch targets, revenue guidance, or manufacturing readiness metrics tied to 2027 and 2028.